ASMB
Assembly Biosciences, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
35.00
▲ 1.47 (4.38%)
MARKET · —
Price
Open
33.53
Prev close
33.53
Day high
35.62
Day low
33.86
Volume
340.47K
Market cap
$700.00M
P/E (TTM)
27.73
52W range
20.23 – 39.71
Trailing performance
Returnvs SPY
1W
+4.34%
+5.7%
1M
+36.32%
+32.6%
3M
+29.74%
+26.6%
6M
+19.58%
+8.5%
YTD
+1.09%
-11.2%
1Y
+31.47%
+11.5%
3Y
+201.58%
+127.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$700.00M
Enterprise value$381.99M
Revenue (TTM)$74.84M
Gross profit$11.19M
EBITDA$-8.69M
Net income$-42.00K
EPS (TTM)$1.24
Free cash flow$-27.87M
Total cash$320.36M
Total debt$2.35M
Book value / share$15.40
Shares outstanding20.36M
Float9.17M
Short % of float15.83%
Dividend yield—
Beta (5Y)1.09
Valuation & profitability ratios
Trailing P/E27.73
Forward P/E-18.24
PEG ratio—
Price / sales—
Price / book2.23
EV / revenue5.10
EV / EBITDA-43.97
Gross margin14.95%
Operating margin-47.44%
Profit margin-0.06%
Return on equity-0.03%
Return on assets-2.67%
Debt / equity0.77
Current ratio13.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $72.30M | $28.52M | $7.16M | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$6.12M | -$40.18M | -$61.23M | -$93.09M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$6.12M | -$40.18M | -$61.23M | -$93.09M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.53 | -0.20 | +61.9% |
| Mar 2026 | -0.64 | -0.54 | +15.2% |
| Dec 2025 | -0.85 | 2.48 | +392.9% |
| Sep 2025 | -0.65 | -0.72 | -10.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.35 | 2 | $7.93M | -26.5% |
| Next quarter | 1.37 | 2 | $32.52M | -23.4% |
| Current year | 0.43 | 2 | $62.02M | -14.2% |
| Next year | -1.89 | 2 | $32.25M | -48.0% |
Analyst targets & ownership
Mean target$50.00
High target$62.00
Low target$43.00
Implied upside42.86%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders27.66%
Held by institutions69.34%
Institutions holding124
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+746.14K
Net buying
Buy transactions
11
746.70K shares
Sell transactions
3
554 shares
Net transactions
+14
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
5.63M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 17, 26 | BJORKQUIST JEANETTE M Officer |
SELL | 29 | $674 | Direct |
| May 26, 26 | GILEAD SCIENCES INC Beneficial Owner of more than 10% of a Class of Security |
STOCK | 471.70K | $12.50M | Direct |
| Mar 30, 26 | BJORKQUIST JEANETTE M Officer |
SELL | 328 | $8.76K | Direct |
| Mar 30, 26 | WHITE NICOLE S Officer |
SELL | 197 | $5.26K | Direct |
| Mar 27, 26 | OKAZAKI JASON A Chief Executive Officer |
STOCK | 50.75K | $0 | Direct |
| Mar 27, 26 | OKAZAKI JASON A Chief Executive Officer |
STOCK | 94.25K | $0 | Direct |
| Mar 27, 26 | DELANEY WILLIAM E IV Officer |
STOCK | 14.00K | $0 | Direct |
| Mar 27, 26 | DELANEY WILLIAM E IV Officer |
STOCK | 26.00K | $0 | Direct |
| Mar 27, 26 | BJORKQUIST JEANETTE M Officer |
STOCK | 3.50K | $0 | Direct |
| Mar 27, 26 | BJORKQUIST JEANETTE M Officer |
STOCK | 6.50K | $0 | Direct |
| Mar 27, 26 | WHITE NICOLE S Officer |
STOCK | 14.00K | $0 | Direct |
| Mar 27, 26 | WHITE NICOLE S Officer |
STOCK | 26.00K | $0 | Direct |
| Mar 27, 26 | GAGGAR ANUJ Officer |
STOCK | 14.00K | $0 | Direct |
| Mar 27, 26 | GAGGAR ANUJ Officer |
STOCK | 26.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BJORKQUIST JEANETTE M |
Officer | 14.56K | Sale |
DELANEY WILLIAM E IV |
Officer | 60.33K | Stock Award(Grant) |
GAGGAR ANUJ |
Officer | 42.69K | Stock Award(Grant) |
GILEAD SCIENCES INC |
Beneficial Owner of more than 10% of a Class of Security | 4.98M | Stock Award(Grant) |
HOUGHTON MICHAEL |
Director | — | Purchase |
OKAZAKI JASON A |
Chief Executive Officer | 163.35K | Stock Award(Grant) |
SCHORNSTEIN ALEXANDER |
Beneficial Owner of more than 10% of a Class of Security | 728.11K | Purchase |
WHITE NICOLE S |
Officer | 37.48K | Sale |
Moving averages & technicals
SMA 10
30.79
+13.69% from price
SMA 20
28.35
+21.25% from price
SMA 50
26.97
+27.47% from price
SMA 100
27.40
+27.72% from price
SMA 200
29.22
+17.66% from price
EMA 12
30.86
+13.42% from price
EMA 26
28.94
+20.92% from price
EMA 50
27.92
+25.38% from price
RSI (14)
70.0
Neutral
MACD (12,26,9)
1.92
Hist 0.79
ATR (14)
1.81
5.27% of price
Realised vol 30D
66.2%
Annualised
Bollinger upper
34.71
20, 2σ
Bollinger lower
22.00
20, 2σ
50 / 200 cross
Death
26.97 vs 29.22
Trend bias
Above 200
+17.66%
Risk profile
Beta vs SPY
1.27
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
66.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-42.2%
Peak to trough
Max drawdown 5Y
-83.3%
Peak to trough
ATR 14
1.81
5.27% of price
Beta (reported)
1.09
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.17
Call-heavy session
Put / call open interest
0.38
Positioning, not flow
Max pain
30.00
-12.7% from spot
ATM implied vol
73.1%
Nearest strike to spot
Skew (10% OTM)
+108.8%
Puts bid over calls
Call volume
47
Contracts, this expiry
Put volume
8
Contracts, this expiry
Heaviest call OI
35.00
119 contracts
Heaviest put OI
30.00
54 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
New Strong Buy Stocks for August 21st
Zacks · 1d ago
Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice
Zacks · 2d ago
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet
Zacks · 2d ago
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 9d ago
Assembly Biosciences: Q2 Earnings Snapshot
Associated Press · 9d ago
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
GlobeNewswire · 9d ago
BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 12d ago
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
MarketBeat · 75d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.